A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1, Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
- Evidence population
- Human clinical study registration
- Participants
- 177
- Population
- ALL · 50 Years
- Duration
- 2020-10-28 to 2026-08-25
- Intervention
- Zifibancimig; Ranibizumab; Port Delivery Platform
- Comparator
- Part 3: PD With Ranibizumab
- Outcomes measured
- Percentage of Participants With Ocular and Systemic (Non-ocular) Adverse Events (AEs) — Part 1: Baseline up to Week 24;…; Percentage of Participants With Ocular AEs During the Post-operative and Follow-up Periods — Parts 2 and 3: From Day 1…; Percentage of Participants With Adverse Events of Special Interest (AESIs) Including Ocular AESIs — Part 1: Baseline up…; Percentage of Participants With Ocular AESIs During the Post-operative and Follow-up Periods — Parts 2 and 3: From Day…; Duration of Ocular AESIs — Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up to Week 48; Duration of Ocular AESIs During the Post-operative and Follow-up Periods — Parts 2 and 3: From Day 1 to Week 4 and duri…; Percentage of Participants With Adverse Device Effects (ADEs) — Parts 2 and 3: Baseline up to Week 48; Duration of ADEs — Parts 2 and 3: Baseline up to Week 48; Percentage of Participants With Anticipated Serious ADEs (ASADEs) — Parts 2 and 3: Baseline up to Week 48; Duration of ASADEs — Parts 2 and 3: Baseline up to Week 48; Change From Baseline in Early Treatment Diabetic Retinopathy Study - Best Corrected Visual Acuity (ETDRS-BCVA) Score at…; Maximum Observed Concentration (Cmax) of Zifibancimig in Blood and Aqueous Humor (AH) — Part 1: Baseline up to Week 24;…; Time of Maximum Concentration Observed (Tmax) of Zifibancimig in Blood and AH — Part 1: Baseline up to Week 24; Parts 2…; Concentration at the End of a Dosing Interval Before the Next Dose Administration (Ctrough) of Zifibancimig in Blood an…; Area Under the Curve (AUC) of Zifibancimig in Blood and AH — Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up…; Percentage of Participants Who did not Meet Supplemental Treatment Criteria for the PD Implant With Zifibancimig — Part…; Percentage of Participants Who Gained or Lost ≥15, ≥10 ≥5 or ≥0 Letters in ETDRS-BCVA Score From Baseline to Week 48 —…; Change From Baseline in Central Subfield Thickness (CST) at Week 48 — Part 3: Baseline, and Week 48; Change From Baseline Over Time in CST — Part 3: Baseline to end of follow-up period (up to Week 144)
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.